COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease (EFFECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01933022
Recruitment Status : Terminated (Termination due to high current screen rate failure and unreliable PSA mRNA assay.)
First Posted : August 30, 2013
Last Update Posted : March 9, 2017
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe Ltd. )

Brief Summary:
The purpose of this study is to investigate the effect of the study medication (Eligard®) on cancer markers (in the blood) of prostate cancer.

Condition or disease Intervention/treatment Phase
Metastatic Prostate Cancer Drug: Eligard Phase 4

Detailed Description:

The main objective of the study is to explore the effect of Eligard® on the following prostate cancer biomarkers:

Testosterone in serum, Prostate Specific Antigen (PSA) in serum, Prostate Cancer Antigen (PCA3 score) in urine, PSA mRNA in blood/Peripheral Blood Mononuclear Cell (PBMC), PCA3 mRNA in blood/PBMC, Transmembrane protease, serine 2-Ets Related Gene (TMPRSS2-ERG) mRNA in blood/PBMC

A blood sample for RNA analysis will also be collected and stored for future investigation in patients giving specific informed consent.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard® 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer
Study Start Date : August 2014
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Single Arm: Eligard
Single Arm
Drug: Eligard
Subcutaneous Injection
Other Name: Leuprorelin acetate

Primary Outcome Measures :
  1. Changes from baseline of Testosterone levels in serum [ Time Frame: Baseline to 6 months ]
  2. Changes from baseline of PSA level in serum [ Time Frame: Baseline to 6 months ]
  3. Changes from baseline of PCA3 score in urine [ Time Frame: Baseline to 6 months ]
  4. Changes from baseline of Number of PSA mRNA copies in blood/PBMC [ Time Frame: Baseline to 6 months ]
  5. Changes from baseline of Number of PCA3 mRNA copies in blood/PBMC [ Time Frame: Baseline to 6 months ]
  6. Changes from baseline of Number of TMPRSS2-ERG mRNA copies in blood/PBMC [ Time Frame: Baseline to 6 months ]

Secondary Outcome Measures :
  1. Number of Adverse Events from screening to the end of study visit (as reported by the investigator based on Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.3) [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed metastatic prostate cancer for whom androgen deprivation therapy (ADT) is indicated.
  • Non-castrate level of testosterone (≥ 8 nmol/L (230 ng/dL)) at screening.
  • Serum PSA ≥ 5 ng/mL at screening.
  • Eastern Cooperative Oncology Group (ECOG) score of 0-2
  • A life expectancy of at least 12 months.
  • Is able to tolerate injection of study drug and comply with the study requirements.
  • Positive blood PSA mRNA at screening. A positive PSA mRNA in PBMCs (defined as exceeding the Limit of Detection [LoD] for the central lab assay, i.e. ≥ 10 copies per Polymerase Chain Reaction, PCR).

Exclusion Criteria:

  • History of bilateral orchidectomy.
  • History of any hormonal treatment/therapy with GnRH agonist, GnRH anti-agonist within 6 months of enrolment.
  • Treatment with anti-androgens (except where used to prevent testosterone flare up, starting up to 2 weeks prior to Eligard injection, according to local treatment guidelines), 5-α reductase inhibitors, estrogens and/or other any investigational hormone-derivative within 3 months of enrolment or 5-times the half-life, whichever is longer.
  • Any previous treatment with chemotherapy treatment for prostate cancer prior to the screening visit or within 6 months prior to screening for any other cancer.
  • Patients previously treated for cancer with hormonal therapy in whom treatment was stopped due to lack of efficacy, progression of the disease or lack of tolerability.
  • Previous treatments for cancer (including prostate cancer) within 6 months prior to enrolment: immunotherapy, external beam radiotherapy, brachytherapy, thermotherapy, or biological response modifiers (e.g. cytokines).
  • Known or suspected spinal cord compression or evidence of spinal metastases with risk of spinal compression.
  • Uni- or bilateral ureteric obstruction.
  • Requiring concomitant use of anti-androgens during the course of the study (except where used to prevent testosterone flare up, starting up to 2 weeks prior to Eligard injection and continuing for up to 3 weeks, according to local treatment guidelines).
  • Previous or concomitant malignancies at other sites except effectively treated non-melanoma skin cancer or an effectively treated malignancy that has been in remission for at least 5 years.
  • Major surgery within 2 months prior to enrolment.
  • Total bilirubin > 1.5 times the upper limit of normal (ULN) at screening. This will not apply to subjects with Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of hemolysis or hepatic pathology), who will be allowed in consultation with the sponsor.
  • Participation in any clinical study within ≤ 1 month prior to screening (or 5 half lives of the drugs under investigation, whichever is greater).
  • Not available for follow-up assessments or unable to comply with study requirements.
  • Known or suspected hypersensitivity to leuprorelin acetate, to other GnRH agonists or to any of the excipients of Eligard.
  • Male subjects who are intending to donate sperm within 9 months following the injection of Eligard
  • Male subjects and their female spouses/partners who are of childbearing potential and are NOT using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continuing for 9 months from the time of the Eligard injection. Acceptable forms include:

    • Established use of oral, injected or implanted hormonal methods of contraception.
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS).
    • Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
  • Absolute neutrophil count < 1,500/μL, platelet count < 100,000/μL, and hemoglobin < 5.6 mmol/L (9 g/dL) at screening.
  • Alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) > 2 times ULN at screening.
  • Creatinine > 177 μmol/L (2 mg/dL) at screening.
  • Albumin ≤ 30 g/L (3.0 g/dL) at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01933022

Layout table for location information
Site NL31005 St. Antonius ziekenhuis
Nieuwegein, Netherlands, 3435 CM
Site NL31004 Radboudumc
Nijmegen, Netherlands, 6525 GA
Site NL31001 Canisius-Wilhelmina Ziekenhuis
Nijmegen, Netherlands, 6532 SZ
Sponsors and Collaborators
Astellas Pharma Europe Ltd.
Layout table for investigator information
Study Chair: Clinical Study Manager Astellas Pharma Europe Ltd.
Additional Information:
Layout table for additonal information
Responsible Party: Astellas Pharma Europe Ltd. Identifier: NCT01933022    
Other Study ID Numbers: EGD-EC-005
2012-000101-69 ( EudraCT Number )
First Posted: August 30, 2013    Key Record Dates
Last Update Posted: March 9, 2017
Last Verified: March 2017
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Europe Ltd. ):
Metastatic prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents